Fz002

Phase 1

NNational Institute of Allergy and Infectious Diseases (NIAID)

Fz002 is one of 29 therapeutic programs targeting Clostridium Difficile Infection. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Clostridium Difficile InfectionNot yet recruiting

Clostridium Difficile InfectionPhase 1

Not yet recruiting

Competition

Competitive Landscape

53 competitors in Clostridium Difficile Infection

#DrugCompanyPhaseTrials

Dificlir

Merck & Co.

Approved

10 2

Vancocin

HHikma Pharmaceuticals LLC

Approved

21 3

ZINPLAVA

Merck & Co.

Approved

4 4

Prilosec

DDexcel Pharma Technologies Ltd.

Approved

—5

Alinia

RRomark Laboratories L.C.

Phase 3

1 6

Imodium

KKenvue Brands

Phase 3

1 7

Flagyl

DDePuy Orthopaedics

Phase 2

3 8

Glutamine

MK-6072

2 10

MK-3415A

Merck & Co.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 1Not yet recruiting

Clostridium Difficile Infection

NCT07649096

Clinical

Trials by Indication[1]

Clostridium Difficile Infection1 trial

A Phase 1 Trial to Evaluate an Orally Ingested Probiotic Yeast Genetically Modified to Express a Tetra-specific Anti-toxin for Clostridioides Difficile

Not yet recruiting·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT07649096·86 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Fz002. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Fz002. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — National Institute of Allergy and Infectious Diseases (NIAID) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: NNational Institute of Allergy and Infectious Diseases (NIAID)

Fz002

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Clostridium Difficile Infection1 trial

References

Drug Info

Quick Facts

Related News